Clonidine and Primary hyperaldosteronism - a phase IV clinical study of FDA data

Summary:

Primary hyperaldosteronism is reported as a side effect among people who take Clonidine (clonidine), especially for people who are female, 60+ old, also take Nifedipine,.

The phase IV clinical study analyzes which people have Primary hyperaldosteronism when taking Clonidine. It is created by eHealthMe based on reports of 63,883 people who have side effects when taking Clonidine from the FDA, and is updated regularly.

What is Clonidine?

Clonidine has active ingredients of clonidine. It is often used in high blood pressure. eHealthMe is studying from 65,644 Clonidine users. Check the latest studies of Clonidine.

What is Primary hyperaldosteronism?

Primary hyperaldosteronism (too much aldosterone is produced by the adrenal glands) is found to be associated with 12 drugs and 65 conditions by eHealthMe. Check the latest studies of Primary hyperaldosteronism.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

63,883 people reported to have side effects when taking Clonidine.
Among them, 12 people (0.02%) have Primary hyperaldosteronism.

Could Clonidine cause Primary hyperaldosteronism?

Among these 12 people:

What is the gender of people who have Primary hyperaldosteronism when taking Clonidine? *

female: 100 %
male: 0.0 %

What is the age of people who have Primary hyperaldosteronism when taking Clonidine? *

What are other drugs people take besides Clonidine? *

What are other side effects people have besides Primary hyperaldosteronism? *

Fatigue (feeling of tiredness): 11 people, 91.67%
Renin Decreased: 10 people, 83.33%
Blood Aldosterone Increased: 10 people, 83.33%
Ill-Defined Disorder: 9 people, 75.00%
Vitreous Haemorrhage (intraocular (inside the eye) bleeding): 1 person, 8.33%
Secondary Hypertension (elevated blood pressure that results from an underlying, identifiable, often correctable cause): 1 person, 8.33%
Retinal Haemorrhage (bleeding from retina): 1 person, 8.33%
Retinal Exudates (discharge from retina): 1 person, 8.33%
Neovascularisation (development of tiny, abnormal, leaky blood vessels inside the eye): 1 person, 8.33%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Clonidine and have Primary hyperaldosteronism?

- Check whether Primary hyperaldosteronism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Clonidine:

Clonidine (65,644 reports)

Browse all side effects of Clonidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Primary hyperaldosteronism:

Primary hyperaldosteronism (12 drugs)

Browse all the conditions that are associated with Primary hyperaldosteronism:

Primary hyperaldosteronism (65 conditions)

Related publications that referenced our studies

Teimoory M, Arefi M, Behnoush B, Bastani B, "Promethazine and Treatment Refractory Agitation in Clonidine Toxicity", International Journal of Medical Toxicology and Forensic Medicine, 2013 Mar .
Teimoory M, Arefi M, Behnoush B, Bastani B, "Promethazine and Treatment Refractory Agitation in Clonidine Toxicity", International Journal of Medical Toxicology and Forensic Medicine, 2013 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on clonidine (the active ingredients of Clonidine) and Clonidine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.